Uptrend on the daily chart: above its 50- and 200-day averages · 50-day above the 200-day · SuperTrend up since Sep 4 · above the Ichimoku cloud · RSI 100 (overbought) · MACD below its signal
None of the 29 investors followed here reported a position in MOTS in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a MOTS trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for MOTS.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 100.0 | 0.0 | +100.0% | ||
| 2025 | -50.0 | 0.0 | 0.0 | 0.0 | 200.0 | 0.0 | -66.7 | 0.0 | -90.0 | 900.0 | 0.0 | 0.0 | −50.0% |
| 2024 | -44.3 | -4.2 | -35.4 | -82.7 | 136.9 | -65.3 | 12.1 | -52.7 | 13.2 | -97.3 | -90.0 | 100.0 | −100.0% |
| 2023 | 25.0 | -12.9 | 6.4 | -20.5 | -12.1 | -1.5 | -4.3 | -20.5 | -11.7 | 34.4 | -47.5 | -73.2 | −89.9% |
| 2022 | -23.6 | -1.2 | 2.1 | -26.8 | 6.0 | 0.8 | -29.0 | -18.0 | -25.3 | -19.6 | -32.0 | -37.3 | −91.0% |
| 2021 | 51.9 | 0.7 | -16.6 | 14.9 | -26.6 | 2.0 | -7.7 | -18.9 | -11.4 | -11.2 | -19.9 | -4.7 | −50.7% |
| 2020 | -10.9 | -30.9 | -52.2 | 69.2 | 7.9 | 7.3 | -7.6 | -12.3 | -8.7 | -24.1 | 26.0 | 1.4 | −58.6% |
| 2019 | 31.8 | 4.4 | -8.9 | 1.8 | -14.6 | -10.6 | -10.9 | -3.7 | -23.8 | -12.6 | 8.5 | 22.0 | −26.4% |
| 2018 | -10.4 | -2.7 | 25.5 | 31.4 | -6.1 | -5.2 | -20.3 | -21.8 | -14.3 | -9.1 | −37.8% |
No analyst coverage for this instrument.
Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.